⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12854186 | 0.77 | PSIP1 (0.32) | — | |
| SCHEMBL9391841 | 0.76 | — | — | |
| SCHEMBL20224681 | 0.76 | — | — | |
| SCHEMBL2904883 | 0.76 | — | — | |
| SCHEMBL1177716 | 0.76 | — | — | |
| SCHEMBL21621365 | 0.76 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL29868226 | 0.73 | — | — | |
| SCHEMBL11480923 | 0.73 | LMNA (0.36) | — | |
| SCHEMBL19548154 | 0.73 | — | — | |
| SCHEMBL9864562 | 0.71 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57159758-A | — | — | None | — | — | JP | disclosed |
| EP-4582106-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING MUTANT FC REGION | Daiichi Sankyo Company, Limited (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250207169-A1 | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| CN-119744182-A | Antibody drug conjugates comprising a mutant Fc region | 第一三共株式会社 | 2025-04-01 | — | — | CN | disclosed |
| EP-4488378-A1 | METHOD FOR PRODUCING FC-CONTAINING MOLECULE | Daiichi Sankyo Company, Limited (JP) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804983-A | Method for producing Fc-containing molecule | 第一三共株式会社 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024048490-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING MUTANT FC REGION | 第一三共株式会社 | 2024-03-07 | — | — | WO | disclosed |
| WO-2023167238-A1 | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE | 第一三共株式会社 | 2023-09-07 | — | — | WO | disclosed |
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3194030-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | New York Blood Center, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-1458381-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053437-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-07-03 | — | — | WO | disclosed |
| US-5336778-A | Substituted triazoles as angiotensin II antagonists | MERCK & CO., INC. (US) | 1994-08-09 | — | — | US | disclosed |
| EP-0515546-A4 | TRIAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | — | 1993-05-12 | — | — | EP | disclosed |
| US-5177095-A | Hypotensive agents | MERCK & CO., INC. (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0515546-A1 | TRIAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | disclosed |
| CN-1059529-A | [3,2-C] pyrazolyl of androgen antagonist and [3,2-d] triazolyl steroid | SCHERING AG (DE) | 1992-03-18 | — | — | CN | disclosed |
| WO-1991011909-A1 | TRIAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0409332-A2 | Substituted triazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-23 | — | — | EP | disclosed |
| JP-S57159758-A | PREPARATION OF BETA-LACTAM | NIPPON CHEMIPHAR CO LTD | 1982-10-01 | — | — | JP | disclosed |